|Bid||0.660 x 1000|
|Ask||1.230 x 800|
|Day's Range||0.820 - 0.945|
|52 Week Range||0.660 - 2.480|
|Beta (3Y Monthly)||2.52|
|PE Ratio (TTM)||79.82|
|Earnings Date||Nov 6, 2018 - Nov 12, 2018|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||6.30|
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -75.67%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?
The Beverly Hills, California-based company said it had a loss of 14 cents per share. The biotechnology company posted revenue of $219,200 in the period. Its adjusted revenue was $219,000. In the final ...
To Host Conference Call and Webcast Today at 4:30 p.m. ET LOS ANGELES, Nov. 13, 2018 -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on.
Capricor Therapeutics (CAPR) announced today that it will meet with the U.S. Food and Drug Administration (FDA) in December to discuss clinical trial design, surrogate or intermediate endpoints and manufacturing processes for CAP-1002, Capricor’s novel cell therapy. Currently, patients are being enrolled in the HOPE-2 clinical trial, which is investigating CAP-1002 as a therapy for the treatment of Duchenne muscular dystrophy. The in-person meeting is part of the expedited review process afforded to Capricor for its CAP-1002 product candidate after being granted the Regenerative Medicine Advanced Therapy (RMAT) designation by the FDA in February 2018.
Capricor Chief Financial Officer A.J. Bergmann will provide the company’s corporate update during the 9-11 a.m. GMT conference session on Sunday, November 11. Action Duchenne plans to stream the presentation on its Facebook page.
Capricor (CAPR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Capricor Therapeutics (CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, will report its third quarter of 2018 financial results and corporate update shortly after the NASDAQ market close on Tuesday, November 13. Capricor Therapeutics, Inc. (CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders.
Presentation to Focus on Company’s Therapeutic Pipeline for Duchenne Muscular Dystrophy and other Rare Diseases LOS ANGELES, Nov. 02, 2018 -- Capricor Therapeutics, Inc..
The American Society of Exosomes and Microvesicles meeting, which started on Saturday, brings together a diverse array of American and international scientists with interests in the fields of exosomes, microvesicles, exRNAs and bacterial outer membrane vesicles. Dr. Marbán provided a presentation on Sunday about the regenerative possibilities of exosome-based therapies.
While some investors are already well versed in financial metrics (hat tip), this article is for those who would like to learn about Return On Equity (ROE) and why it Read More...
NEW YORK, Oct. 17, 2018 -- In new independent research reports released early this morning, Market Source Research released its latest key findings for all current investors,.
I’ve been keeping an eye on Capricor Therapeutics Inc (NASDAQ:CAPR) because I’m attracted to its fundamentals. Looking at the company as a whole, as a potential stock investment, I believeRead More...
NEW YORK, Aug. 23, 2018-- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Live ...
Capricor (CAPR) delivered earnings and revenue surprises of -7.69% and -1.46%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?
On a per-share basis, the Beverly Hills, California-based company said it had a loss of 14 cents. The biotechnology company posted revenue of $404,000 in the period. In the final minutes of trading on ...
Each day, the Benzinga Pro news team highlights several stocks with Trading Idea potential. Be the first to see them by becoming a Benzinga Pro user ! Netflix, Inc. (NASDAQ: NFLX ) was trading lower by ...
Capricor Therapeutics Inc (NASDAQ:CAPR) is a stock with outstanding fundamental characteristics. When we build an investment case, we need to look at the stock with a holistic perspective. In theRead More...
Capricor Therapeutics Inc (NASDAQ:CAPR) is currently trading at a trailing P/E of 13.4x, which is lower than the industry average of 25.8x. While this makes CAPR appear like a greatRead More...